Selectively Targeting the DNA Binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer

Dalal K, et al., pii: jbc.M114.553818, J Biol Chem, 2014

This study detailed the screening, identification and characterization of small molecules that are targeted to bind specifically to the androgen receptor DNA-binding domain (DBD) and abolish androgen receptor transcriptional activity without involving the ligand binding domain (LBD). This work suggests a new approach for the treatment of recurrent and metastatic prostate cancer. Binding studies using Streptavidin biosensors were performed on the Octet RED system.

Read More